Damora Therapeutics, Inc. (DMRA) SEC Filings

Damora Therapeutics, Inc. filed an initial statement of beneficial ownership for Andrew Cheng. He is identified as a director of the company and this Form 3 establishes his status as a reporting person. The filing notes an attached Power of Attorney authorizing SEC reporting actions.

Damora Therapeutics, Inc., now a Cayman Islands exempted company, files a post‑effective amendment to its automatic shelf registration to reflect its redomestication from Delaware to the Cayman Islands completed on July 16, 2026. The business, assets, liabilities, management, fiscal year and Nasdaq Capital Market listing under the symbol “DMRA” remain the same. Each share of common and preferred stock, as well as options, RSUs and warrants of the former Delaware entity, converted on a one‑for‑one basis into corresponding Cayman ordinary and preferred shares and derivative awards.

The shelf registration covers an indeterminate amount of ordinary shares, preferred shares, debt securities, warrants and units, with specific terms to be set in future supplements. A sales agreement with TD Cowen permits “at the market” offerings of ordinary shares up to $150,000,000, of which $29,968,064 has already been sold, leaving $120,031,936 available; TD Cowen earns up to a 3.0% commission on gross sales. Net proceeds are intended for preclinical and clinical development, manufacturing for antibody programs, broader research and development, working capital and general corporate purposes, and potentially strategic licensing or acquisitions.

Damora Therapeutics, Inc., a clinical‑stage biotech focused on mutCALR‑driven myeloproliferative neoplasms, reported substantially higher operating expenses and losses for the three and six months ended June 30, 2026 as it scaled R&D following the acquisition of Pre‑Acquisition Damora and entry into its Paragon collaboration.

Cash and cash equivalents were $540.5 million at June 30, 2026, up from $257.6 million at year‑end 2025, driven mainly by a February 2026 underwritten equity offering yielding net proceeds of $295.5 million and an at‑the‑market program that raised $29.3 million. Total assets were $543.6 million against total liabilities of $27.6 million, and stockholders’ equity was $516.1 million.

For Q2 2026, research and development expense rose to $25.5 million and general and administrative to $9.5 million, leading to a net loss of $31.2 million for the quarter and $59.0 million year‑to‑date, compared with $3.4 million and $6.0 million in the prior‑year periods. Operating cash use for the first half was $42.5 million

Lori Firmani filed a notice to sell up to 1,800 shares of DMRA common stock through Maxim Group on the NASDAQ, with an aggregate value of $55,980.00 and an anticipated sale date of 08/05/2026. The shares relate to options dated 01/04/2023 issued by the company and are to be sold for cash.

The filing also lists DMRA common stock sales during the prior three months: 7,615 shares sold on 06/22/2026 for $192,882.00 and 242 shares sold on 05/19/2026 for $5,915.00.

BlackRock, Inc. reported a passive ownership stake in Damora Therapeutics Inc. common stock on a Schedule 13G. BlackRock and certain of its business units beneficially own 3,143,576 shares of Damora common stock, representing 5.1 % of the outstanding class as of June 30, 2026.

BlackRock has sole voting power over 3,072,238 shares and sole dispositive power over 3,143,576 shares, with no shared voting or dispositive power reported. Various underlying clients and investors have the right to receive dividends or sale proceeds from these shares, but no individual person holds more than five percent of Damora’s outstanding common stock through these arrangements.

Damora Therapeutics, Inc. completed a redomestication from Delaware to the Cayman Islands effective July 16, 2026, via a Plan of Conversion. The company now exists as a Cayman Islands exempted company while continuing to operate as Damora Therapeutics, Inc. and to be treated as a U.S. corporation for federal tax purposes.

Each outstanding share of Delaware common stock automatically converted into one ordinary share, par value $0.00001 per share, of the Cayman company, and each preferred share converted into the corresponding Cayman preferred share. Options, rights and restricted stock units now relate to the same number of Cayman ordinary shares. Nasdaq trading continues under the symbol DMRA, with a new CUSIP G2646Y104 from the open on July 20, 2026, without trading interruption.

The company’s internal affairs and shareholder rights are now governed by Cayman law and the Cayman Memorandum and Articles of Association, and certain shareholder rights changed as described in the prior proxy statement. Business, management, obligations, assets, liabilities, material contracts, SEC reporting status and accounting treatment are stated to be unaffected. On July 16, 2026, Damora also entered into new indemnification agreements with all directors and executive officers, providing indemnification and advancement of expenses subject to specified terms.

Damora Therapeutics, Inc. General Counsel Winslow Garrett reported routine equity compensation activity involving restricted stock units (RSUs) and a small share sale tied to taxes. On July 3, 2026, 680 RSUs were settled into 680 shares of common stock at a stated price of $0.00 per share as part of their scheduled vesting from a January 3, 2024 award. On the same date, 640 RSUs from this award remained outstanding. On July 6, 2026, 245 shares of common stock were sold at $29.98 per share to cover tax obligations in connection with the RSU vesting under the company’s 2020 Equity Incentive Plan, which the filing describes as a mandated, non-discretionary sale. Following these transactions, Garrett holds 2,289 shares of Damora Therapeutics common stock directly.